Yoshikazu Inoue

List of Publications by Year in Descending Order

126 papers	12,821 citations	42 h-index	113 g-index
134 ext. papers	17,225 ext. citations	9.7 avg, IF	5.68 L-index

#	Paper	IF	Citations
126	Platelet-derived growth factor can predict survival and acute exacerbation in patients with idiopathic pulmonary fibrosis.. *Journal of Thoracic Disease*, **2022**, 14, 278-294	2.6	0
125	Inhibition of lung microbiota-derived proapoptotic peptides ameliorates acute exacerbation of pulmonary fibrosis.. *Nature Communications*, **2022**, 13, 1558	17.4	2
124	Anti-Myxovirus Resistance Protein-1 Immunoglobulin A Autoantibody in Idiopathic Pulmonary Fibrosis.. *Canadian Respiratory Journal*, **2022**, 2022, 1107673	2.1	
123	Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.. *American Journal of Respiratory and Critical Care Medicine*, **2022**, 205, e18-e47	10.2	38
122	Preventing infection after synthetic expander implantation in patients undergoing breast reconstruction. **2022**, 8, 42-45		
121	Hemosiderin-Laden Macrophages in Bronchoalveolar Lavage: Predictive Role for Acute Exacerbation of Idiopathic Interstitial Pneumonias.. *Canadian Respiratory Journal*, **2021**, 2021, 4595019	2.1	0
120	Reduced risk of recurrent pneumothorax for sirolimus therapy after surgical pleural covering of entire lung in lymphangioleiomyomatosis. *Orphanet Journal of Rare Diseases*, **2021**, 16, 466	4.2	0
119	Idiopathic pulmonary fibrosis: Physician and patient perspectives on the pathway to care from symptom recognition to diagnosis and disease burden. *Respirology*, **2021**,	3.6	1
118	B cell-activating factors in autoimmune pulmonary alveolar proteinosis. *Orphanet Journal of Rare Diseases*, **2021**, 16, 115	4.2	1
117	Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society. *Radiology*, **2021**, 298, 550-566	20.5	15
116	Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper From the Fleischner Society. *Chest*, **2021**, 159, 1107-1125	5.3	15
115	Diagnostic yield and safety of bronchofiberscopy for pulmonary alveolar proteinosis. *Respiratory Investigation*, **2021**, 59, 757-765	3.4	0
114	Prognostic significance of serum cytokines during acute exacerbation of idiopathic interstitial pneumonias treated with thrombomodulin. *BMJ Open Respiratory Research*, **2021**, 8,	5.6	1
113	Current monitoring and treatment of progressive fibrosing interstitial lung disease: a survey of physicians in Japan, the United States, and the European Union. *Current Medical Research and Opinion*, **2021**, 37, 327-339	2.5	2
112	Genetic determinants of risk in autoimmune pulmonary alveolar proteinosis. *Nature Communications*, **2021**, 12, 1032	17.4	4
111	Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial. *European Respiratory Journal*, **2021**,	13.6	4
110	2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease. *Respiratory Investigation*, **2021**, 59, 709-740	3.4	2

109	Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial. *Respiratory Medicine*, **2021**, 187, 106574	4.6	1
108	Drug-related pneumonitis with radiographic hypersensitivity pneumonitis pattern: Three case series. *Respiratory Medicine Case Reports*, **2021**, 34, 101498	1.2	0
107	Using Data on Survival with Idiopathic Pulmonary Fibrosis to Estimate Survival with Other Types of Progressive Fibrosis Interstitial Lung Disease: A Bayesian Framework.. *Advances in Therapy*, **2021**, 39, 1045	4.1	0
106	Validation of a new serum granulocyte-macrophage colony-stimulating factor autoantibody testing kit. *ERJ Open Research*, **2020**, 6,	3.5	4
105	Is corticosteroid use truly not associated with improved outcomes in AE-IPF?. *Respirology*, **2020**, 25, 659	3.6	1
104	The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner Society. *Radiology*, **2020**, 296, 172-180	20.5	471
103	Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. *Lancet Respiratory Medicine,the*, **2020**, 8, 453-460	35.1	154
102	Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society. *Lancet Respiratory Medicine,the*, **2020**, 8, 726-737	35.1	77
101	High-resolution CT features distinguishing usual interstitial pneumonia pattern in chronic hypersensitivity pneumonitis from those with idiopathic pulmonary fibrosis. *Japanese Journal of Radiology*, **2020**, 38, 524-532	2.9	4
100	Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype. *Chest*, **2020**, 158, 646-659	5.3	33
99	Characteristics and prognosis of interstitial pneumonias complicated with pneumomediastinum. *Respiratory Investigation*, **2020**, 58, 262-268	3.4	
98	MAPK mutations and cigarette smoke promote the pathogenesis of pulmonary Langerhans cell histiocytosis. *JCI Insight*, **2020**, 5,	9.9	11
97	Lymphoplasmacytic lymphoma involving the mediastinum and the lung, followed by amyloidosis: A surgically and genetically proven case. *Respiratory Medicine Case Reports*, **2020**, 31, 101313	1.2	0
96	Autoimmune Pulmonary Alveolar Proteinosis Complicated with Sarcoidosis: the Clinical Course and Serum Levels of Anti-granulocyte-macrophage colony-stimulating Factor Autoantibody. *Internal Medicine*, **2020**, 59, 2539-2546	1.1	3
95	Thrombomodulin Alfa for Acute Exacerbation of Idiopathic Pulmonary Fibrosis. A Randomized, Double-Blind Placebo-controlled Trial. *American Journal of Respiratory and Critical Care Medicine*, **2020**, 201, 1110-1119	10.2	28
94	Clinical significance of serum anti-granulocyte-macrophage colony-stimulating factor autoantibodies in patients with sarcoidosis and hypersensitivity pneumonitis. *Orphanet Journal of Rare Diseases*, **2020**, 15, 272	4.2	5
93	Massive atelectasis by mucoid impaction in an asthma patient during treatment with anti-interleukin-5 receptor antibody. *Respirology Case Reports*, **2020**, 8, e00599	0.9	1
92	Insights into pathogenesis and clinical implications in myositis-associated interstitial lung diseases. *Current Opinion in Pulmonary Medicine*, **2020**, 26, 507-517	3	3

91	Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline. *American Journal of Respiratory and Critical Care Medicine*, **2020**, 202, e36-e69	10.2	175
90	Acute exacerbation of idiopathic interstitial pneumonias related to chemotherapy for lung cancer: nationwide surveillance in Japan. *ERJ Open Research*, **2020**, 6,	3.5	7
89	Seroradiologic prognostic evaluation of acute exacerbation in patients with idiopathic interstitial pneumonia: a retrospective observational study. *Journal of Thoracic Disease*, **2020**, 12, 4132-4147	2.6	0
88	Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis. *New England Journal of Medicine*, **2020**, 383, 1635-1644	59.2	24
87	Long-term treatment with nintedanib in Asian patients with idiopathic pulmonary fibrosis: Results from INPULSIS -ON. *Respirology*, **2020**, 25, 410-416	3.6	12
86	Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study. *Lancet Respiratory Medicine,the*, **2019**, 7, 771-779	35.1	34
85	Inhaled GM-CSF for Pulmonary Alveolar Proteinosis. *New England Journal of Medicine*, **2019**, 381, 923-932	59.2	58
84	Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. *New England Journal of Medicine*, **2019**, 381, 1718-1727	59.2	585
83	Analysis of systemic lupus erythematosus-related interstitial pneumonia: a retrospective multicentre study. *Scientific Reports*, **2019**, 9, 7355	4.9	17
82	Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 200, 199-208	10.2	53
81	Recombinant thrombomodulin for acute exacerbation in idiopathic interstitial pneumonias. *Respirology*, **2019**, 24, 658-666	3.6	11
80	Serum vascular endothelial growth factor-D as a diagnostic and therapeutic biomarker for lymphangioleiomyomatosis. *PLoS ONE*, **2019**, 14, e0212776	3.7	11
79	Analysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangioleiomyomatosis. *European Respiratory Journal*, **2019**, 53,	13.6	18
78	Nationwide cloud-based integrated database of idiopathic interstitial pneumonias for multidisciplinary discussion. *European Respiratory Journal*, **2019**, 53,	13.6	26
77	Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials. *BMJ Open Respiratory Research*, **2019**, 6, e000397	5.6	66
76	Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 200, 1146-1153	10.2	33
75	Successful Sirolimus Treatment of Lymphangioleiomyomatosis in a Hepatitis B Virus Carrier. *Internal Medicine*, **2019**, 58, 569-574	1.1	0
74	Long-Term Safety and Efficacy of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD. *International Journal of COPD*, **2019**, 14, 2993-3002	3	3

73	Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD: A Subgroup Analysis of the KRONOS Study. *International Journal of COPD*, **2019**, 14, 2979-2991	3	6
72	Lung function outcomes in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis. *Respiratory Medicine*, **2019**, 146, 42-48	4.6	20
71	Corticosteroids in acute exacerbations of idiopathic interstitial pneumonias: Time to debate - Reply. *Respirology*, **2018**, 23, 546-547	3.6	2
70	Influence of surface light scattering and glistenings of intraocular lenses on visual function 15 to 20 years after surgery. *Journal of Cataract and Refractive Surgery*, **2018**, 44, 219-225	2.3	7
69	Pulmonary alveolar proteinosis in adults: pathophysiology and clinical approach. *Lancet Respiratory Medicine,the*, **2018**, 6, 554-565	35.1	75
68	Efficacy and safety of transbronchial lung biopsy for the diagnosis of lymphangioleiomyomatosis: A report of 24 consecutive patients. *Respirology*, **2018**, 23, 331-338	3.6	13
67	Japanese guideline for the treatment of idiopathic pulmonary fibrosis. *Respiratory Investigation*, **2018**, 56, 268-291	3.4	41
66	Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. *Lancet Respiratory Medicine,the*, **2018**, 6, 138-153	35.1	452
65	Blood testing in the diagnosis of pulmonary alveolar proteinosis - AuthorsSreply. *Lancet Respiratory Medicine,the*, **2018**, 6, e55	35.1	1
64	PatientsSperceptions and patient-reported outcomes in progressive-fibrosing interstitial lung diseases. *European Respiratory Review*, **2018**, 27,	9.8	24
63	Comorbid connective tissue diseases and autoantibodies in lymphangioleiomyomatosis: a retrospective cohort study. *Orphanet Journal of Rare Diseases*, **2018**, 13, 182	4.2	1
62	Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 198, e44-e68	10.2	1426
61	Classification of idiopathic interstitial pneumonias using anti-myxovirus resistance-protein 1 autoantibody. *Scientific Reports*, **2017**, 7, 43201	4.9	8
60	High-dose prednisolone after intravenous methylprednisolone improves prognosis of acute exacerbation in idiopathic interstitial pneumonias. *Respirology*, **2017**, 22, 1363-1370	3.6	23
59	A Semiquantitative Computed Tomographic Grading System for Evaluating Therapeutic Response in Pulmonary Alveolar Proteinosis. *Annals of the American Thoracic Society*, **2017**, 14, 1403-1411	4.7	7
58	Nintedanib in Japanese patients with idiopathic pulmonary fibrosis: A subgroup analysis of the INPULSIS randomized trials. *Respirology*, **2017**, 22, 750-757	3.6	24
57	Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study. *European Respiratory Journal*, **2017**, 50,	13.6	50
56	Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. *BMJ Open Respiratory Research*, **2017**, 4, e000212	5.6	107

55	Risk factors for stomatitis in patients with lymphangioleiomyomatosis during treatment with sirolimus: A multicenter investigator-initiated prospective study. *Pharmacoepidemiology and Drug Safety*, **2017**, 26, 1182-1189	2.6	
54	Disease severity staging system for idiopathic pulmonary fibrosis in Japan. *Respirology*, **2017**, 22, 1609-1614	3.6	9
53	Lymphangioleiomyomatosis Diagnosis and Management: High-Resolution Chest Computed Tomography, Transbronchial Lung Biopsy, and Pleural Disease Management. An Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guideline. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 196, 1337-1348	10.2	97
52	Lymphangioleiomyomatosis **2016**, 1243-1259.e12		1
51	Heterogeneity of incidence and outcome of acute exacerbation in idiopathic interstitial pneumonia. *Respirology*, **2016**, 21, 1431-1437	3.6	26
50	Pulmonary Fibrosis on High-Resolution CT of Patients With Pulmonary Alveolar Proteinosis. *American Journal of Roentgenology*, **2016**, 207, 544-51	5.4	16
49	Efficacy and Safety of Long-Term Sirolimus Therapy for Asian Patients with Lymphangioleiomyomatosis. *Annals of the American Thoracic Society*, **2016**, 13, 1912-1922	4.7	33
48	Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management. *American Journal of Respiratory and Critical Care Medicine*, **2016**, 194, 748-61	10.2	160
47	Subgroup analysis of Asian patients in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis. *Respirology*, **2016**, 21, 1425-1430	3.6	22
46	Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS. *American Journal of Respiratory and Critical Care Medicine*, **2016**, 193, 178-85	10.2	169
45	Whole lung lavage therapy for pulmonary alveolar proteinosis: a global survey of current practices and procedures. *Orphanet Journal of Rare Diseases*, **2016**, 11, 115	4.2	62
44	Reductions in pulmonary function detected in patients with lymphangioleiomyomatosis: An analysis of the Japanese National Research Project on Intractable Diseases database. *Respiratory Investigation*, **2016**, 54, 193-200	3.4	15
43	Outcome of corticosteroid administration in autoimmune pulmonary alveolar proteinosis: a retrospective cohort study. *BMC Pulmonary Medicine*, **2015**, 15, 88	3.5	35
42	All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis. *Respiratory Investigation*, **2015**, 53, 232-41	3.4	46
41	A mathematical model to predict protein wash out kinetics during whole-lung lavage in autoimmune pulmonary alveolar proteinosis. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2015**, 308, L105-17	5.8	3
40	Autoimmune Pulmonary Alveolar Proteinosis Following Pulmonary Aspergillosis. *Internal Medicine*, **2015**, 54, 3177-80	1.1	3
39	Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. *European Respiratory Journal*, **2015**, 45, 1382-92	13.6	124
38	Utility of expiratory thin-section CT for fibrotic interstitial pneumonia. *Acta Radiologica*, **2014**, 55, 1050-5	2	14

37	Secondary pulmonary alveolar proteinosis complicating myelodysplastic syndrome results in worsening of prognosis: a retrospective cohort study in Japan. *BMC Pulmonary Medicine*, **2014**, 14, 37	3.5	33
36	Standardized serum GM-CSF autoantibody testing for the routine clinical diagnosis of autoimmune pulmonary alveolar proteinosis. *Journal of Immunological Methods*, **2014**, 402, 57-70	2.5	60
35	Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis. *Respiratory Investigation*, **2014**, 52, 136-43	3.4	31
34	Tracheobronchial lesions in eosinophilic pneumonia. *Respiratory Investigation*, **2014**, 52, 21-7	3.4	4
33	Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. *New England Journal of Medicine*, **2014**, 370, 2071-82	59.2	2337
32	Duration of benefit in patients with autoimmune pulmonary alveolar proteinosis after inhaled granulocyte-macrophage colony-stimulating factor therapy. *Chest*, **2014**, 145, 729-737	5.3	43
31	CYFRA 21-1 as a disease severity marker for autoimmune pulmonary alveolar proteinosis. *Respirology*, **2014**, 19, 246-252	3.6	22
30	Design of the INPULSIS trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis. *Respiratory Medicine*, **2014**, 108, 1023-30	4.6	69
29	Light chain (ratio of GM-CSF autoantibodies is associated with disease severity in autoimmune pulmonary alveolar proteinosis. *Clinical Immunology*, **2013**, 149, 357-64	9	9
28	Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial. *Lancet Respiratory Medicine,the*,	35.1	119
27	An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. *American Journal of Respiratory and Critical Care Medicine*, **2013**, 188, 733-48	10.2	2176
26	Cytomegalovirus infection during immunosuppressive therapy for diffuse parenchymal lung disease. *Respirology*, **2013**, 18, 117-24	3.6	6
25	Efficacy and safety of sirolimus in lymphangioleiomyomatosis. *New England Journal of Medicine*, **2011**, 364, 1595-606	59.2	724
24	Long-term follow-up high-resolution CT findings in non-specific interstitial pneumonia. *Thorax*, **2011**, 66, 61-5	7.3	52
23	Anti-IL-6 receptor antibody causes less promotion of tuberculosis infection than anti-TNF- antibody in mice. *Clinical and Developmental Immunology*, **2011**, 2011, 404929		20
22	Inhaled granulocyte/macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosis. *American Journal of Respiratory and Critical Care Medicine*, **2010**, 181, 1345-54	10.2	156
21	Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases. *Chest*, **2010**, 138, 674-81	5.3	143
20	Lymphangioleiomyomatosis **2010**, 1496-1515		

19	Quantitative CT in chronic obstructive pulmonary disease: inspiratory and expiratory assessment. *American Journal of Roentgenology*, **2009**, 192, 267-72	5.4	62
18	Diagnostic potential of serum VEGF-D for lymphangioleiomyomatosis. *New England Journal of Medicine*, **2008**, 358, 199-200	59.2	98
17	Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. *American Journal of Respiratory and Critical Care Medicine*, **2008**, 177, 752-62	10.2	305
16	The epidemiology of lymphangioleiomyomatosis in Japan: a nationwide cross-sectional study of presenting features and prognostic factors. *Respirology*, **2007**, 12, 523-30	3.6	81
15	Enhanced mast cell chymase expression in human idiopathic interstitial pneumonia. *International Journal of Molecular Medicine*, **2007**,	4.4	1
14	DNA vaccine using hemagglutinating virus of Japan-liposome encapsulating combination encoding mycobacterial heat shock protein 65 and interleukin-12 confers protection against Mycobacterium tuberculosis by T cell activation. *Vaccine*, **2006**, 24, 1191-204	4.1	35
13	Epidemiological and clinical features of idiopathic pulmonary alveolar proteinosis in Japan. *Respirology*, **2006**, 11 Suppl, S55-60	3.6	30
12	Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model. *Vaccine*, **2005**, 23, 2132-5	4.1	54
11	Granulocyte-macrophage colony-stimulating factor and lung immunity in pulmonary alveolar proteinosis. *American Journal of Respiratory and Critical Care Medicine*, **2005**, 171, 1142-9	10.2	90
10	Pulmonary alveolar proteinosis. *Clinics in Chest Medicine*, **2004**, 25, 593-613, viii	5.3	69
9	Serum neutralizing capacity of GM-CSF reflects disease severity in a patient with pulmonary alveolar proteinosis successfully treated with inhaled GM-CSF. *Respiratory Medicine*, **2004**, 98, 1227-30	4.6	35
8	Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis. *American Journal of Respiratory and Critical Care Medicine*, **2002**, 166, 765-73	10.2	101
7	Mast cell basic fibroblast growth factor in silicosis. *American Journal of Respiratory and Critical Care Medicine*, **2000**, 161, 2026-34	10.2	28
6	Serological diagnosis of idiopathic pulmonary alveolar proteinosis. *American Journal of Respiratory and Critical Care Medicine*, **2000**, 162, 658-62	10.2	167
5	Morphometric analysis of insulin-like growth factor-I localization in lung tissues of patients with idiopathic pulmonary fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **1998**, 158, 1626-35	10.2	69
4	Pulmonary epithelial cell injury and alveolar-capillary permeability in berylliosis. *American Journal of Respiratory and Critical Care Medicine*, **1997**, 156, 109-15	10.2	98
3	KL-6, a human MUC1 mucin, is chemotactic for human fibroblasts. *American Journal of Respiratory Cell and Molecular Biology*, **1997**, 17, 501-7	5.7	126
2	KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease. *The American Review of Respiratory Disease*, **1993**, 148, 637-42		209

1	SECRETORY EFFECTS OF VASOACTIVE INTESTINAL POLYPEPTIDE (VIP), ADRENALINE AND CARBACHOL IN ISOLATED LOBULES OF THE RAT PAROTID GLAND . *Biomedical Research*, **1982**, 3, 384-389	15	17